Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

Cytochrom P450 2C9

Das CYP2C9-Gen kodiert ein Cytochrom P450 Enzym, welches insbesondere für die Metabolisierung von Tolbutamin, Warfarin (Phenprocoumon) und anderen eine Rolle zu spielen scheint. So sind bestimmte Variationen gefunden worden, bei denen die Patienten unter oralen Antikontrazeptiva eine Blutungsneigung aufweisen.

Gentests:

Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Multiplex ligationsabhängige Amplifikation
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Coumarin-Resistenz
CYP2A6
CYP2C9
CYP4F2
VKORC1
Störungen im Cytochrom P450-System
CYP1A2
CYP2A6
CYP2C9
CYP2D6
CYP3A4
CYP4F2
Siponimod-Intoleranz
CYP2C9
Siponimod-Intoleranz
CYP2C9

Referenzen:

1.

Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.

external link
2.

Steward DJ et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

external link
3.

Gray IC et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.

external link
4.

Li T et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

external link
5.

Sanderson S et al. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

external link
6.

King BP et al. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

external link
7.

Fichtlscherer S et al. (2004) Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.

external link
8.

Kirchheiner J et al. (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

external link
9.

Williams PA et al. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin.

external link
10.

Higashi MK et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

external link
11.

Leung AY et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

external link
12.

Xie HG et al. (2001) Molecular basis of ethnic differences in drug disposition and response.

external link
13.

Aithal GP et al. (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.

external link
14.

Thum T et al. (2000) Gene expression in distinct regions of the heart.

external link
15.

Kidd RS et al. (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

external link
16.

Aithal GP et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

external link
17.

et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data.

external link
18.

Tate SK et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

external link
19.

NCBI article

NCBI 1559 external link
20.

OMIM.ORG article

Omim 601130 external link
21.

Orphanet article

Orphanet ID 241965 external link
22.

Wikipedia Artikel

Wikipedia DE (Cytochrom_P450_2C9) external link
Update: 14. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz